设计,合成和生物评估Chromeno[3,4-b]xanthones作为阿尔茨海默病的多功能代理
Daniela Malafaia1, Natércia F Brás2, Anna Sampietro3
1LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
ACS chemical neuroscience
|August 6, 2025
概括
新型染色体[3,4-b]桑在阿尔茨海默病 (AD) 治疗方面表现有前途. 这些化合物抑制胆化酶和粉样蛋白聚合,而化合物11r表现出平衡的特征和潜力透大脑.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 呈现出重大未满足的医疗需求,需要创新的治疗策略.
- 目前的治疗方法往往针对单一的途径,突出显示了对多功能药物的需求.
研究的目的:
- 探索染色体[3,4-b]桑作为阿尔茨海默病的新型多功能支架.
- 合成和评估这些化合物的胆酶抑制和抗粉样蛋白聚合活性.
主要方法:
- 通过 (E) -2-styrylchromones的循环化合成chromo[3,4-b]xanthones的合成.
- 在体外测定胆酶抑制 (AChE,BChE) 和粉样β (Aβ) 聚合.
- 分子对接和动力学模拟以阐明结合机制.
- 在体外,TEM和细胞研究以评估Aβ聚合干扰.
- 在形预测类似药物的特性,包括血脑屏障 (BBB) 透性.
主要成果:
- 化合物10和11q-s显示出强有力的和选择性的胆酶抑制 (IC501.7-9.0μM).
- 观察到显著的抗粉胺活性,在50μM时抑制超过50%.
- 化合物11r表现出与AD相关的目标相比,一个平衡的多功能配置.
- 分子模拟显示了11r与AChE,BChE和Aβ42纤维的良好结合相互作用.
- 化合物11r在体外和细胞模型中有效地破坏了Aβ聚合,显示了BBB的透性和安全性.
结论:
- 染色体[3,4-b]桑是阿尔茨海默病多功能药物的有前途的一类.
- 化合物11r由于其平衡的活性和有利的类似药物的特性,具有显著的治疗潜力.
- 这种支架扩大了开发新型小分子治疗AD的化学空间.
更多相关视频
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.5K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
